Sugi Predict

Sugi Predict / Compounds / SCHEMBL574383

SCHEMBL574383

SCHEMBL574383

CC(C)n1cc([N+](=O)[O-])cn1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ RXFP1 Q9HBX9 4/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ ACHE P22303 2/20 0.42
▸ F2 P00734 2/20 0.41
▸ PLAU P00749 2/20 0.41
▸ ELANE P08246 2/20 0.41
▸ LMNA P02545 3/20 0.41
▸ MAPK1 P28482 2/20 0.40
▸ ALDH1A1 P00352 3/20 0.36
▸ MAPT P10636 2/20 0.36
▸ POLB P06746 1/20 0.36
▸ KMT2A Q03164 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ RECQL P46063 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ HIF1A Q16665 1/20 0.35
▸ ATM Q13315 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25438635 0.84 RXFP1 (0.44) RXFP1SMN1; SMN2F2PLAUELANE
SCHEMBL31085494 0.82 ACHE (0.48) RXFP1SMN1; SMN2ACHEF2PLAU
SCHEMBL23229770 0.82 RXFP1 (0.51) RXFP1SMN1; SMN2F2PLAUELANE
SCHEMBL19010799 0.81 RXFP1 (0.44) RXFP1SMN1; SMN2F2PLAUELANE
SCHEMBL20518839 0.81 RXFP1 (0.44) RXFP1SMN1; SMN2F2PLAUELANE
SCHEMBL27275347 0.81 RXFP1 (0.44) RXFP1SMN1; SMN2ACHEF2PLAU
SCHEMBL19010737 0.81 RXFP1 (0.56) RXFP1SMN1; SMN2F2PLAUELANE
SCHEMBL3264887 0.81 RXFP1 (0.43) RXFP1SMN1; SMN2F2PLAUELANE
SCHEMBL23675079 0.79 SMN1; SMN2 (0.46) RXFP1SMN1; SMN2ACHEF2PLAU
SCHEMBL30962934 0.79 SMN1; SMN2 (0.44) RXFP1SMN1; SMN2F2PLAUELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12624023-B2 Sulfonylurea derivatives and uses thereof NodThera Limited (GB) 2026-05-12 — — US disclosed
EP-3983407-B1 SULFONYLUREA DERIVATIVES AND USES THEREOF NODTHERA LTD (GB) 2025-11-12 — — EP disclosed
EP-4637738-A2 INHIBITORS OF JAK2 Llydaw Therapeutics, Inc. (US) 2025-10-29 — — EP disclosed
US-12358879-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-07-15 — — US disclosed
US-12281101-B2 Bicyclic lactams and methods of use thereof GENENTECH, INC. (US) 2025-04-22 — — US disclosed
EP-4046688-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2025-04-09 — — EP disclosed
CN-114222739-B Sulfonylurea derivatives and their use 诺瑟拉有限公司 2025-02-11 — — CN disclosed
WO-2024137548-A2 INHIBITORS OF JAK2 Llydaw Therapeutics, Inc. (US) 2024-06-27 — — WO disclosed
EP-3760625-B1 BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES HOFFMANN LA ROCHE (CH) 2024-03-27 — — EP disclosed
US-20230322683-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-12 — — US disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 — — US disclosed
WO-2008034008-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC. (US) 2008-03-20 — — WO disclosed
CN-101072758-A Quinazoline derivatives ASTRAZENECA AB (SE) 2007-11-14 — — CN disclosed
WO-2007113565-A1 NAPHTHYRIDINE DERIVATIVES AS ANTI-CANCER AGENTS ASTRAZENECA AB (SE) 2007-10-11 — — WO disclosed
WO-2007099323-A2 QUINOLINE DERIVATIVES ASTRAZENECA AB (SE) 2007-09-07 — — WO disclosed
WO-2007099335-A1 QUINOLINE DERIVATIVES FOR TREATING CANCER ASTRAZENECA AB (SE) 2007-09-07 — — WO disclosed
WO-2007099317-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2007-09-07 — — WO disclosed
WO-2007099326-A1 QUINOLINE DERIVATIVES ASTRAZENECA AB (SE) 2007-09-07 — — WO disclosed
EP-1802591-A1 QUINAZOLINE DERIVATIVES AstraZeneca AB (SE) 2007-07-04 — — EP disclosed
WO-2006040520-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2006-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322683-A1 HETEROCYCLIC COMPOUND PARK7, SMN1; SMN2, SNCA RXFP1 4149/4885SMN1; SMN2 2/4885ACHE 37/4885
US-12281101-B2 Bicyclic lactams and methods of use thereof LSS, LPXN, CYP1B1 RXFP1 631/4885SMN1; SMN2 3272/4885ACHE 1396/4885
US-12358879-B2 Heterocyclic compound PARK7, SMN1; SMN2, SNCA RXFP1 4149/4885SMN1; SMN2 2/4885ACHE 37/4885
US-12624023-B2 Sulfonylurea derivatives and uses thereof PYCARD, NOD1, NLRP3 RXFP1 745/4885SMN1; SMN2 2289/4885ACHE 4433/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 RXFP1 2757/4885SMN1; SMN2 4182/4885ACHE 2582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.